

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-64111-05
Application Number	Not yet assigned
Filed	10/5/2004
First Named Inventor	Martin
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
BH		5,530,101	25 June 1996	Queen <i>et al.</i>
BH		6,096,728	01 Aug 2000	Collins <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
BH		WIPO/PCT	93/01289	21 Jan 1993	Crowe <i>et al.</i>
BH		WIPO/PCT	00/25816	11 May 2000	Pinna <i>et al.</i>
BH		WIPO/PCT	2004/003156	08 Jan 2004	Leonard <i>et al.</i>

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
BH		BELLAMY <i>et al.</i> , "The Distribution of Interleukin-2 Receptor Bearing Lymphocytes in Multiple Sclerosis: Evidence for a Key Role of Activated Lymphocytes," <i>Clin. Exp. Immunol.</i> , 61:248-256 (1985)
BH		GIORELLI <i>et al.</i> , "IFN-beta1a Modulates the Expression of CTLA-4 and CD28 Splices in Human Mononuclear Cells: Induction of Soluble Isoforms," <i>J. Interferon Cytokine Res.</i> , 21:809-12 (2001)
BH		"Industry News (Transplantation): FDA Approval of Zenapax for Kidney Transplants Announced," <i>Cancer Weekly</i> , p.2 (1997)

EXAMINER SIGNATURE: /Bruce Hissong/

DATE CONSIDERED: 08/03/2006

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	10/519311
		Application Number	Not yet assigned
		Filed	Herewith
		First Named Inventor	Martin
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
BH		JUNGHANS <i>et al.</i> , "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders," <i>Cancer Res.</i> , 50:1495-1502 (1990), abstract only.	
		KHOURY <i>et al.</i> , "Changes in Activated T Cells in the Blood Correlate with Disease Activity in Multiple Sclerosis," <i>Arch Neurol</i> , 57:1183-1189 (2000)	
		LEHKY <i>et al.</i> , "Reduction in HTLV-I Proviral Load and Spontaneous Lymphoproliferation in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis Patients Treated with Humanized Anti-Tac," <i>Ann. Neurol.</i> , 44:942-947 (1998)	
		MARWICK, "Scientists Recall Progress and Promise of Translational Research," <i>J. Natl. Cancer Inst.</i> , 93:13-15 (2001)	
		NUSSENBLATT <i>et al.</i> , "Treatment of Noninfectious Intermediate and Posterior Uveitis with the Humanized Anti-Tac mAb: A Phase I/II Clinical Trial," <i>Proc. Natl. Acad. Sci.</i> , 96:7462-7466 (1999)	
		PATY <i>et al.</i> , "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis," <i>Neurology</i> 43:662-667, 1993	
		POSEY <i>et al.</i> , "New Drugs for 1997," www.ascp.com/public/pubs/tcp/1997/apr/newdrugs , 21pp. (1997)	
		"Study of Zenapax in the Treatment of Multiple Sclerosis," www.multiple-sclerosis.org/news/Nov2000/ZenapaxMS , 4pp. (November 2000)	
		WANDINGER <i>et al.</i> , "Complex Immunomodulatory Effects of Interferon-beta in Multiple Sclerosis Include the Upregulation of T Helper 1-associated Marker Genes," <i>Ann. Neurol.</i> , 50(3):349-57 (2001)	

EXAMINER SIGNATURE: /Bruce Hissong/	DATE CONSIDERED: 08/03/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

